| Literature DB >> 26112433 |
Richard G White1, Avi J Hakim2, Matthew J Salganik3, Michael W Spiller2, Lisa G Johnston4, Ligia Kerr5, Carl Kendall6, Amy Drake2, David Wilson7, Kate Orroth8, Matthias Egger9, Wolfgang Hladik2.
Abstract
OBJECTIVES: Respondent-driven sampling (RDS) is a new data collection methodology used to estimate characteristics of hard-to-reach groups, such as the HIV prevalence in drug users. Many national public health systems and international organizations rely on RDS data. However, RDS reporting quality and available reporting guidelines are inadequate. We carried out a systematic review of RDS studies and present Strengthening the Reporting of Observational Studies in Epidemiology for RDS Studies (STROBE-RDS), a checklist of essential items to present in RDS publications, justified by an explanation and elaboration document. STUDY DESIGN ANDEntities:
Keywords: Biomedical research/methods; Cross-sectional studies; Epidemiologic research design; Epidemiologic studies; Guidelines as topic; Guidelines as topic/standards; Humans; Observation/methods; Practice guidelines as topic; Publishing/standards; Research design
Mesh:
Year: 2015 PMID: 26112433 PMCID: PMC4669303 DOI: 10.1016/j.jclinepi.2015.04.002
Source DB: PubMed Journal: J Clin Epidemiol ISSN: 0895-4356 Impact factor: 6.437
Fig. 1(A) Number of published peer-reviewed studies using respondent-driven sampling 1990–July 2013. * = part year. (B) World map showing number of published peer-reviewed studies using respondent-driven sampling 1990–July 2013, by country.
STROBE-RDS Statement Checklist
| Item | # | Original STROBE checklist for cross-sectional studies | STROBE-RDS checklist |
|---|---|---|---|
| Title and abstract | 1 | (a) Indicate the study's design with a commonly used term in the title or the abstract | (a) Indicate |
| (b) Provide in the abstract an informative and balanced summary of what was done and what was found | (b) Provide in the abstract an informative and balanced summary of what was done and what was found | ||
| Introduction | |||
| Background/rationale | 2 | Explain the scientific background and rationale for the investigation being reported | Explain the scientific background and rationale for the investigation being reported |
| Objectives | 3 | State specific objectives, including any prespecified hypotheses | State-specific objectives, including any prespecified hypotheses |
| Methods | |||
| Study design | 4 | (a) Present key elements of study design early in the article | (a) Present key elements of study design early in the article |
| Setting | 5 | (a) Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection | |
| Participants | 6 | (a) Give the eligibility criteria and the sources and methods of selection of participants | (a) Give the eligibility criteria and the sources and methods of selection of participants. |
| Variables | 7 | (a) Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable | |
| Data sources/measurement | 8 | (a) For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group | (a) For each variable of interest, give sources of data and details of methods of |
| Bias | 9 | Describe any efforts to address potential sources of bias | Describe any efforts to address potential sources of bias |
| Study size | 10 | Explain how the study size was arrived at | Explain how the study size was arrived at |
| Quantitative variables | 11 | Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why | Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why |
| Statistical methods | 12 | (a) Describe all statistical methods, including those used to control for confounding | |
| (b) Describe any methods used to examine subgroups and interactions | (c) Describe any methods used to examine subgroups and interactions | ||
| (c) Explain how missing data were addressed | (d) Explain how missing data were addressed | ||
| (d) If applicable, describe analytical methods taking account of sampling strategy | |||
| (e) Describe any sensitivity analyses | (e) Describe any sensitivity analyses | ||
| Results | |||
| Participants | 13 | (a) Report the numbers of individuals at each stage of the study—for example, numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analyzed | |
| (b) Give reasons for nonparticipation at each stage | (b) Give reasons for nonparticipation at each stage | ||
| (c) Consider use of a flow diagram | (c) Consider use of a flow diagram | ||
| Descriptive data | 14 | (a) Give characteristics of study participants (e.g., demographic, clinical, social) and information on exposures and potential confounders | (a) Give characteristics of study participants (e.g., demographic, clinical, social) and, |
| (b) Indicate the number of participants with missing data for each variable of interest | (b) Indicate the number of participants with missing data for each variable of interest | ||
| Outcome data | 15 | Report numbers of outcome events or summary measures | |
| Main results | 16 | (a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (e.g., 95% confidence intervals). Make clear which confounders were adjusted for and why they were included | (a) Give unadjusted |
| (b) Report category boundaries when continuous variables were categorized | (b) Report category boundaries when continuous variables were categorized | ||
| (c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful period | |||
| Other analyses | 17 | Report other analyses done—for example, analyses of subgroups and interactions and sensitivity analyses | Report other analyses done—for example, analyses of subgroups and interactions, sensitivity analyses, |
| Discussion | |||
| Key results | 18 | Summarize key results with reference to study objectives | Summarize key results with reference to study objectives |
| Limitations | 19 | Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias | Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias |
| Interpretation | 20 | Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence | Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence |
| Generalizability | 21 | Discuss the generalizability (external validity) of the study results | Discuss the generalizability (external validity) of the study results |
| Other information | |||
| Funding | 22 | Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based | Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based |
Abbreviations: STROBE-RDS, Strengthening the Reporting of Observational Studies in Epidemiology for respondent-driven sampling; #, number.
Italics highlight changes from STROBE statement checklist for cross-sectional studies [20]. Full details of modifications from [20] are shown in Table S1 in Supplementary Material at www.jclinepi.com.